2026 Q3 - tulosraportti
1 päivä sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 312 | - | - | ||
| 44 506 | - | - | ||
| 20 606 | - | - | ||
| 12 576 | - | - | ||
| 60 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 22.10. | ||
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 23.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·6 t sittenSo I have bought 625,000 for the risk portfolio - which is very small and plays with binary events. It can then sit until 2027-2028 and see if anything happens there.
Have bought so the risk position here is now up to 6.4 million shares. Then we will see going forward.
·1 päivä sittenSøren Bregenholt thanks for our patience :) During his time, the share has ONLY fallen by 99.999 % if we go back from when they started, the share has fallen by 99.9999 % meaning one 9 digit extra. It has been a joke to be an investor at Alligator Bioscience AB, they have made maximal dilution every single time but the funny thing is if they get through and succeed with HLX22 and Henlius gets it marketed and starts selling the medicine then Alligator Bioscience AB can have the potential to rise 10-100 times in a very short time. We will see if they go bankrupt or they are going up by 10-100 times. If they get their Mitazalimab project sold, it could potentially also rise many times, but as Søren just said, it is an agreement that will probably be made based on very little money upfront. I am staying in the share and then it must make or break and if it goes bankrupt then I at least have many years where I do not have to pay tax on share gains and that is positive or... :) It is not going to go bankrupt for the next half year or so because now they have money well into mid-late 2027 Søren Bregenholt and the management of Alligator Bioscience AB should have allied with Saniona and Sprint Bioscience then they might have learned something about how to get lucrative deals closed in the biotech market without continuing to dilute shareholders. Just in the current year, it has fallen by 96.85 % .......... Good day out there and good wind Disclaimer: I own shares in Alligator Bioscience and this is not a recommendation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI may also be wrong in what it has found.
·2 päivää sittenAnyone have any thoughts on tomorrow's results presentation?
poor management where the losses just keep increasing and increasing,,,, business and investments are more about trust than money. abandoned this ship where the rats are eating it from the inside. SELL AND FORGET is my thought- ·7.10.I asked AI and got this answer: what is alligator expected to earn and when on the agreement regarding HLX22 According to the current agreement structure, the Swedish biotech company Alligator Bioscience is entitled to 35% of all milestone payments and royalties that the company AbClon receives from Shanghai Henlius Biotech for the development and sale of HLX22. Following a major strategic realignment in the summer of 2026, where Alligator stopped the in-house development of their previous lead candidate mitazalimab, the HLX22 agreement now constitutes the single most important value creator for the company. Here are the details on what Alligator is expected to earn, as well as when the money will arrive: Expected revenues (What can they earn?) • Historical milestones: Alligator has so far received a total of 3 million USD in early milestone payments under the agreement. • Effective royalty rate: The agreement ensures Alligator an effective royalty of 1.5% to 2.0% (more precisely up to 1.75%) of the total global net sales of HLX22. • Annual potential at peak sales (Peak Sales): Alligator estimates itself that when HLX22 is fully rolled out on the market, it will be able to generate 150 to 450 million Swedish kronor (SEK) annually in pure royalty income – based solely on the gastric cancer indication. • No costs: The absolute major financial advantage is that Henlius finances and drives 100% of the expensive clinical trials. Alligator receives the money as pure profit without having development costs themselves. Timeline (When does the money arrive?) The revenues are directly linked to how fast Henlius can drive the clinical trials through to approval: 1. Additional milestone payments (Short to medium term): Alligator will receive ongoing partial payments as the ongoing global Phase 3 study (HLX22-GC-301) progresses, including when data cuts take place and when official marketing authorization applications (BLA/NDA) are submitted to health authorities (such as the FDA and EMA). 2. The major royalty revenues (Longer term): The annual million amounts in royalties will only start rolling in when HLX22 is officially approved and launched on the market. Since the global Phase 3 study for gastric cancer was initiated in 2025, it will typically take a couple of years of patient follow-up and data processing. Financial analysts point out that Alligator is on track to present a real financial surplus in step with the maturation of the study. Disclaimer: I own shares in Alligator Bioscience and this is not a solicitation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI can also be wrong in what it has found.does not matter what revenues we get on this type of company as they go out to management and CEO in the form of salaries bonuses compensations and is like a large black hole .... antimatter
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 124 637 325 | 124 637 325 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 124 637 325 | 124 637 325 | 0 | 0 |
2026 Q3 - tulosraportti
1 päivä sitten
‧32 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·6 t sittenSo I have bought 625,000 for the risk portfolio - which is very small and plays with binary events. It can then sit until 2027-2028 and see if anything happens there.Have bought so the risk position here is now up to 6.4 million shares. Then we will see going forward.
- ·1 päivä sittenSøren Bregenholt thanks for our patience :) During his time, the share has ONLY fallen by 99.999 % if we go back from when they started, the share has fallen by 99.9999 % meaning one 9 digit extra. It has been a joke to be an investor at Alligator Bioscience AB, they have made maximal dilution every single time but the funny thing is if they get through and succeed with HLX22 and Henlius gets it marketed and starts selling the medicine then Alligator Bioscience AB can have the potential to rise 10-100 times in a very short time. We will see if they go bankrupt or they are going up by 10-100 times. If they get their Mitazalimab project sold, it could potentially also rise many times, but as Søren just said, it is an agreement that will probably be made based on very little money upfront. I am staying in the share and then it must make or break and if it goes bankrupt then I at least have many years where I do not have to pay tax on share gains and that is positive or... :) It is not going to go bankrupt for the next half year or so because now they have money well into mid-late 2027 Søren Bregenholt and the management of Alligator Bioscience AB should have allied with Saniona and Sprint Bioscience then they might have learned something about how to get lucrative deals closed in the biotech market without continuing to dilute shareholders. Just in the current year, it has fallen by 96.85 % .......... Good day out there and good wind Disclaimer: I own shares in Alligator Bioscience and this is not a recommendation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI may also be wrong in what it has found.
- ·2 päivää sittenAnyone have any thoughts on tomorrow's results presentation?poor management where the losses just keep increasing and increasing,,,, business and investments are more about trust than money. abandoned this ship where the rats are eating it from the inside. SELL AND FORGET is my thought
- ·7.10.I asked AI and got this answer: what is alligator expected to earn and when on the agreement regarding HLX22 According to the current agreement structure, the Swedish biotech company Alligator Bioscience is entitled to 35% of all milestone payments and royalties that the company AbClon receives from Shanghai Henlius Biotech for the development and sale of HLX22. Following a major strategic realignment in the summer of 2026, where Alligator stopped the in-house development of their previous lead candidate mitazalimab, the HLX22 agreement now constitutes the single most important value creator for the company. Here are the details on what Alligator is expected to earn, as well as when the money will arrive: Expected revenues (What can they earn?) • Historical milestones: Alligator has so far received a total of 3 million USD in early milestone payments under the agreement. • Effective royalty rate: The agreement ensures Alligator an effective royalty of 1.5% to 2.0% (more precisely up to 1.75%) of the total global net sales of HLX22. • Annual potential at peak sales (Peak Sales): Alligator estimates itself that when HLX22 is fully rolled out on the market, it will be able to generate 150 to 450 million Swedish kronor (SEK) annually in pure royalty income – based solely on the gastric cancer indication. • No costs: The absolute major financial advantage is that Henlius finances and drives 100% of the expensive clinical trials. Alligator receives the money as pure profit without having development costs themselves. Timeline (When does the money arrive?) The revenues are directly linked to how fast Henlius can drive the clinical trials through to approval: 1. Additional milestone payments (Short to medium term): Alligator will receive ongoing partial payments as the ongoing global Phase 3 study (HLX22-GC-301) progresses, including when data cuts take place and when official marketing authorization applications (BLA/NDA) are submitted to health authorities (such as the FDA and EMA). 2. The major royalty revenues (Longer term): The annual million amounts in royalties will only start rolling in when HLX22 is officially approved and launched on the market. Since the global Phase 3 study for gastric cancer was initiated in 2025, it will typically take a couple of years of patient follow-up and data processing. Financial analysts point out that Alligator is on track to present a real financial surplus in step with the maturation of the study. Disclaimer: I own shares in Alligator Bioscience and this is not a solicitation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI can also be wrong in what it has found.does not matter what revenues we get on this type of company as they go out to management and CEO in the form of salaries bonuses compensations and is like a large black hole .... antimatter
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 312 | - | - | ||
| 44 506 | - | - | ||
| 20 606 | - | - | ||
| 12 576 | - | - | ||
| 60 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 22.10. | ||
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 23.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 124 637 325 | 124 637 325 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 124 637 325 | 124 637 325 | 0 | 0 |
2026 Q3 - tulosraportti
1 päivä sitten
‧32 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 22.10. | ||
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 23.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·6 t sittenSo I have bought 625,000 for the risk portfolio - which is very small and plays with binary events. It can then sit until 2027-2028 and see if anything happens there.Have bought so the risk position here is now up to 6.4 million shares. Then we will see going forward.
- ·1 päivä sittenSøren Bregenholt thanks for our patience :) During his time, the share has ONLY fallen by 99.999 % if we go back from when they started, the share has fallen by 99.9999 % meaning one 9 digit extra. It has been a joke to be an investor at Alligator Bioscience AB, they have made maximal dilution every single time but the funny thing is if they get through and succeed with HLX22 and Henlius gets it marketed and starts selling the medicine then Alligator Bioscience AB can have the potential to rise 10-100 times in a very short time. We will see if they go bankrupt or they are going up by 10-100 times. If they get their Mitazalimab project sold, it could potentially also rise many times, but as Søren just said, it is an agreement that will probably be made based on very little money upfront. I am staying in the share and then it must make or break and if it goes bankrupt then I at least have many years where I do not have to pay tax on share gains and that is positive or... :) It is not going to go bankrupt for the next half year or so because now they have money well into mid-late 2027 Søren Bregenholt and the management of Alligator Bioscience AB should have allied with Saniona and Sprint Bioscience then they might have learned something about how to get lucrative deals closed in the biotech market without continuing to dilute shareholders. Just in the current year, it has fallen by 96.85 % .......... Good day out there and good wind Disclaimer: I own shares in Alligator Bioscience and this is not a recommendation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI may also be wrong in what it has found.
- ·2 päivää sittenAnyone have any thoughts on tomorrow's results presentation?poor management where the losses just keep increasing and increasing,,,, business and investments are more about trust than money. abandoned this ship where the rats are eating it from the inside. SELL AND FORGET is my thought
- ·7.10.I asked AI and got this answer: what is alligator expected to earn and when on the agreement regarding HLX22 According to the current agreement structure, the Swedish biotech company Alligator Bioscience is entitled to 35% of all milestone payments and royalties that the company AbClon receives from Shanghai Henlius Biotech for the development and sale of HLX22. Following a major strategic realignment in the summer of 2026, where Alligator stopped the in-house development of their previous lead candidate mitazalimab, the HLX22 agreement now constitutes the single most important value creator for the company. Here are the details on what Alligator is expected to earn, as well as when the money will arrive: Expected revenues (What can they earn?) • Historical milestones: Alligator has so far received a total of 3 million USD in early milestone payments under the agreement. • Effective royalty rate: The agreement ensures Alligator an effective royalty of 1.5% to 2.0% (more precisely up to 1.75%) of the total global net sales of HLX22. • Annual potential at peak sales (Peak Sales): Alligator estimates itself that when HLX22 is fully rolled out on the market, it will be able to generate 150 to 450 million Swedish kronor (SEK) annually in pure royalty income – based solely on the gastric cancer indication. • No costs: The absolute major financial advantage is that Henlius finances and drives 100% of the expensive clinical trials. Alligator receives the money as pure profit without having development costs themselves. Timeline (When does the money arrive?) The revenues are directly linked to how fast Henlius can drive the clinical trials through to approval: 1. Additional milestone payments (Short to medium term): Alligator will receive ongoing partial payments as the ongoing global Phase 3 study (HLX22-GC-301) progresses, including when data cuts take place and when official marketing authorization applications (BLA/NDA) are submitted to health authorities (such as the FDA and EMA). 2. The major royalty revenues (Longer term): The annual million amounts in royalties will only start rolling in when HLX22 is officially approved and launched on the market. Since the global Phase 3 study for gastric cancer was initiated in 2025, it will typically take a couple of years of patient follow-up and data processing. Financial analysts point out that Alligator is on track to present a real financial surplus in step with the maturation of the study. Disclaimer: I own shares in Alligator Bioscience and this is not a solicitation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI can also be wrong in what it has found.does not matter what revenues we get on this type of company as they go out to management and CEO in the form of salaries bonuses compensations and is like a large black hole .... antimatter
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 312 | - | - | ||
| 44 506 | - | - | ||
| 20 606 | - | - | ||
| 12 576 | - | - | ||
| 60 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 124 637 325 | 124 637 325 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 124 637 325 | 124 637 325 | 0 | 0 |